Over-the-counter medication · Osmotic Laxative

polyethylene glycol 3350

Also sold as MiraLAX. MiraLAX treats occasional constipation, which means you have irregular bowel movements.

Data updated 2026-05-15

91,655
FDA reportsOften reported
1
Recall record

What the data shows

polyethylene glycol 3350 (MiraLAX) is an over-the-counter Osmotic Laxative, more reported than most tracked drugs (91,655 FDA reports).

Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.

polyethylene glycol 3350 (MiraLAX) is an over-the-counter Osmotic Laxative. MiraLAX treats occasional constipation, which means you have irregular bowel movements.

MiraLAX is a laxative medicine. It helps to relieve constipation by drawing water into your stool, making it easier to pass.

Drug Pricing (NADAC)

Generic Price

$0.03/unit

Generic Available

Yes (16 manufacturers)

Pricing data from NADAC (CMS), effective December 25, 2024. Compare all drug costs →

NADAC price trail: POLYETHYLENE GLYCOL 3350 POWD

Same CMS presentation as the headline generic unit price above (3 effective dates). Adjacent % compares consecutive NADAC releases for this description only, not a patient out-of-pocket quote. Latest step: -95% vs prior release.

50¢100¢150¢ 2024-102024-122024-12 2.91¢
Effective NADAC / unit vs prior NDCs
October 23, 2024 $1.17/EA - 4
December 18, 2024 $0.5827/GM -50.2% 33
December 25, 2024 $0.0291/GM -95% 1
View Alternatives → Compare with Another Drug → Full Side Effects Report →

What it does

MiraLAX treats occasional constipation, which means you have irregular bowel movements.

Common side effects

Diarrhea, Nausea, Headache

Key warnings

Do not use more than directed unless your doctor tells you to.

The sections below are summarized in plain English from polyethylene glycol 3350's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.

How It Works

MiraLAX is an osmotic laxative. It works by drawing water into your colon. This softens the stool and makes it easier to pass, relieving constipation.

Side Effects (from patient reports)

Based on 91,655 FDA adverse event reports.

Most-reported reactions

Adverse reactions in FAERS for polyethylene glycol 3350, by number of reports

reports

What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.

Source FDA Adverse Event Reporting System (FAERS) As of 2025

Reports over time

Adverse-event reports filed for polyethylene glycol 3350 each year to the FDA Adverse Event Reporting System (FAERS).

02,0004,0006,0008,00010,000 200220052008201120142017202020232025 6,202

Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.

Where polyethylene glycol 3350 sits

polyethylene glycol 3350 has more FDA adverse-event reports than 84% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.

fewest reports most reports

Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is polyethylene glycol 3350; the line is the median (50th percentile).

FDA Adverse Event Report Analysis

Detailed analysis of 91,655 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2002–2025.

Total Reports

91,655

Reports Mentioning Death

6,093

6.6% of reports — not proof of cause

Hospitalization Reports

20,647

Top Indication

Product Used For Unknown Indication

Gender Distribution

Female 50,437 (61%)
Male 32,645 (39%)

Age Distribution

0–17 5,550
18–44 4,908
45–64 11,918
65–74 11,803
75+ 17,576

Most Reported Adverse Reactions (FAERS)

# Reaction Reports
4 DIARRHOEA 6,828
5 NAUSEA 5,306
6 CONSTIPATION 5,098
7 FATIGUE 4,564
9 VOMITING 3,284
10 PAIN 2,927
11 INCORRECT DRUG ADMINISTRATION DURATION 2,837
12 INCORRECT DOSE ADMINISTERED 2,725
13 DEATH 2,717
14 DYSPNOEA 2,703
15 HEADACHE 2,657
16 ASTHENIA 2,622
17 DIZZINESS 2,434
18 ABDOMINAL PAIN 2,419
19 INCORRECT PRODUCT ADMINISTRATION DURATION 2,310

Reactions in Death Reports

DEATH 2,711
NAUSEA 525
SEPSIS 477
CONSTIPATION 461
VOMITING 434
PNEUMONIA 421
DYSPNOEA 420
ANAEMIA 380
FATIGUE 360
ABDOMINAL PAIN 355

Reactions in Hospitalization Reports

NAUSEA 1,945
PNEUMONIA 1,756
CONSTIPATION 1,672
FATIGUE 1,571
VOMITING 1,571
DYSPNOEA 1,507
FALL 1,423
DIARRHOEA 1,373
ASTHENIA 1,326
PAIN 1,275

Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation

Serious Warnings

Do not use more than directed unless your doctor tells you to. Ask a doctor if you are 16 years old or younger.

Common Questions

How quickly does MiraLAX work?
MiraLAX generally produces a bowel movement in 1 to 3 days.
Can I take MiraLAX every day?
Do not use MiraLAX for more than 7 days.
How much MiraLAX should I take?
Adults and children 17 years of age and older should fill the bottle cap to the white section (17 grams) once a day.
Can I mix MiraLAX with any drink?
Yes, you can mix MiraLAX with any beverage, such as cold, hot, or room temperature drinks.
What should I do if MiraLAX doesn't work?
Talk to your doctor if MiraLAX does not relieve your constipation.
Can children take MiraLAX?
Children 16 years of age or under: ask a doctor.
Is it okay to use MiraLAX long term?
No, do not use MiraLAX for more than 7 days.
What if the powder has clumps?
Do not drink if there are any clumps.
How do I know the product is safe to use?
Do not use if the printed foil seal under the cap is missing, open, or broken.
Can I mix MiraLAX with food?
MiraLAX should be mixed with a beverage, not food. Do not combine with starch-based thickeners.
What are the common side effects of polyethylene glycol 3350?
The registry lists Diarrhea, Nausea, Headache, Abdominal pain among the most-reported FAERS reaction terms for polyethylene glycol 3350. The compiled record contains 91,655 FDA adverse-event reports. These counts are not an individual symptom assessment.
What drug class is polyethylene glycol 3350?
polyethylene glycol 3350 belongs to the Osmotic Laxative drug class. It is available over the counter (OTC). MiraLAX treats occasional constipation, which means you have irregular bowel movements.
What pregnancy or breastfeeding source fields are listed for polyethylene glycol 3350?
The FDA label for polyethylene glycol 3350 contains product-specific pregnancy or breastfeeding language. PlainMeds does not apply that source text to an individual.
Has polyethylene glycol 3350 been recalled?
There is 1 recall associated with polyethylene glycol 3350 products. CGMP Deviations: product held outside appropriate storage temperature conditions. Check the recalls section below for full details and affected products.

Active Recalls

Class II June 23, 2022

CGMP Deviations: product held outside appropriate storage temperature conditions.

Family Dollar Stores, Llc.

Other drugs grouped near polyethylene glycol 3350 - same-class peers and common alternatives.

Compare polyethylene glycol 3350 vs alosetron side-by-side →

Compare beyond drug class

Nationwide peers by FAERS volume & death-report share

Two PlainMeds-derived comparison paths for polyethylene glycol 3350: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.

Medication Guides

What the FDA Data Shows for polyethylene glycol 3350

The FDA label for polyethylene glycol 3350 (sold under brand names such as MiraLAX) classifies it as an over-the-counter product in the Osmotic Laxative class. MiraLAX treats occasional constipation, which means you have irregular bowel movements. Official labeling lists 4 commonly reported side effects, including Diarrhea, Nausea, Headache.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 91,655 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. NADAC pricing from CMS shows a generic unit cost of $0.03.

Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history (currently 1 recall record on file), and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.

Last updated: March 21, 2025

PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.

All federal data sources used on this page